How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

ID6221 nemolizumab atopic dermatitis DG to PM for consultation [NoCON] indev.docx

Closed for comments This consultation ended on at   Request commenting lead permission

ID6221 nemolizumab atopic dermatitis DG to PM for consultation [NoCON] indev.docx

Note that this document is not NICE's final guidance on this technology. The recommendations in section 1 may change after consultation.

After consultation:

  • The evaluation committee will meet again to consider the evidence, this evaluation consultation document and comments from the stakeholders.

  • At that meeting, the committee will also consider comments made by people who are not stakeholders.

  • After considering these comments, the committee will prepare the final draft guidance.

  • Subject to any appeal by stakeholders, the final draft guidance may be used as the basis for NICE's guidance on using nemolizumab in the NHS in England.

For further details, see NICE's manual on health technology evaluation.

The key dates for this evaluation are:

  • Closing date for comments: 17 April 2025

  • Second evaluation committee meeting: 07 May 2025

  • Details of the evaluation committee are given in section 4

Comments panel open